Lupin Inks Strategic Deal with Amman Pharma for Biosimilar Market Expansion in MENA Region

10 Nov 2023 , 02:11 PM

Lupin Limited collaborates with Amman Pharmaceuticals Industries for Ranibizumab biosimilar marketing in the Middle East and select territories. The partnership covers countries like Jordan, Saudi Arabia, UAE, Iraq, Lebanon, and other GCC countries.

Ranibizumab is a biosimilar of Lucentis, used to manage neovascular age-related macular degeneration (AMD) and macular edema. The drug is administered through eye injection, inhibiting abnormal blood vessel growth and preventing retina damage.

Collaboration aims to enhance patient access to innovative healthcare solutions in the MENA region. Lupin’s Managing Director, Nilesh Gupta, emphasizes the goal of transforming patients’ lives in the MENA region.

Dr. Cyrus Karkaria, President of Biotechnology at Lupin, underscores the commitment to providing access to advanced biosimilars at affordable costs. Dr. Fadi Alatrash, General Manager of Amman Pharma, highlights the collaboration’s role in strengthening Lupin’s biosimilar portfolio and position in the Ophthalmology market.

Lupin reported a 3.77-fold YoY rise in consolidated net profit at Rs 489.6 crore for Q2 of the current financial year. North America sales for the quarter reached Rs 18,66.6 crore, contributing to 40.4% growth YoY and accounting for 38% of Lupin’s global sales.

For feedback and suggestions, write to us at [e-mail]